Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setanaxib plus pembrolizumab versus placebo plus pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma
ISRCTN63646763Phase 2Completed
- Sponsor
- PRA Health Sciences
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Setanaxib + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoint: Best percentage change in tumor size. Started May 2022; status: completed.
02
Drugs
setanaxib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN63646763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63646763.